Cortica, a San Diego CA-based company focused on clinical services for autism and other neurodevelopmental conditions, raised $60M in series C funding.
The round was led by Longitude Capital with participation from 406 Ventures, Adam Boehler, Questa Capital and Aperture Venture Partners and Silicon Valley Bank, which expanded Cortica’s credit facilities. As part of the financing, Cortica is adding Adam Boehler, CEO of Rubicon Founders, founder of Landmark Health, and former director of the Center for Medicare and Medicaid Innovation (CMMI); and Martha Temple, former CEO of Optum Behavioral Health and market president at Aetna, to its board of directors.
The company intends to use the funds to accelerate growth, expand centers across multiple states, and investigate novel drug, device, and diagnostic technologies through sponsored and NIH-funded research.
Led by co-founders Neil Hattangadi, M.D., CEO, and Suzanne Goh, M.D., BCBA, Pediatric Neurologist and Chief Medical Officer, both Rhodes scholars who met at Harvard Medical School, Cortica provides clinical services for autism and other neurodevelopmental conditions which combine neurology, research-based therapies, and technology into comprehensive care programs for children.
The company is in the process of accelerating growth, expanding centers across multiple states, and investigating novel drug, device, and diagnostic technologies through sponsored and NIH-funded research.